Speaker Profile
M.D., Co-founder and Chief Medical Officer, Adela
Biography
Dr. Hartman is a leader in oncology diagnostics with over 20 years of experience developing clinical cancer tests. Leveraging her expertise across the continuum of care, from early detection to minimal residual disease monitoring, she has spearheaded pivotal trials in risk stratification, cancer screening, and cancer management during her leadership roles at Myriad Genetics and GRAIL. Driven by a passion for innovation, Dr. Hartman cofounded Adela to pioneer a highperforming liquid biopsy utilizing whole methylome technology. With diverse expertise in clinical development, product development and diagnostic platforms, she is translating her deep knowledge into transformative molecular approaches for early diagnosis and tailored treatment.
Session Abstract – PMWC 2024 Silicon Valley
Track Chair: Laura J. van 't Veer, UCSF
- PMWC 2024 Award Ceremony
Pioneer Honoree: David Sidransky, Johns Hopkins
Luminary Honorees: Helmy Eltoukhy & AmirAli Talasaz, Guardant Health - Utilities of Liquid Biopsy in Biomarker Testing
- Laura Vent Veer, UCSF - Status Quo of Clinical Liquid Biopsy
Chair: Helmy Eltoukhy, Guardant Health
- Sadakatsu Ikeda, Tokyo Medical University
- Heather Parsons, Dana-Farber Cancer Institute
- Bruna Pellini, Moffitt Cancer Center
- Sanjay Popat, The Royal Marsden - Liquid Biopsy for Health Monitoring and Disease Prevention (PANEL)
Chair: Anne-Renee Hartman, Adela Bio
- AmirAli Talasaz, Guardant Health
- Heather Parsons, Dana-Farber Cancer Institute
- Mary Pat Lancelotta, Adaptive Bio - Liquid Biopsy in Early Cancer Detection (PANEL)
Chair: Tom Beer, Exact Sciences
- Wendy Rubinstein, Cancer Screening Research Network (CSRN) - Keynote: Pioneering Liquid Nucleic acids Tumor Fragments in Health and Diseases
- David Sidransky, Johns Hopkins - New Approaches in Liquid Biopsy (PANEL)
Chair: Victor Velculescu, Johns Hopkins
- David Sidransky, Johns Hopkins
- Dan Laudau, NY Genome Center
- Daniel De Carvalho, University of Toronto - Global Implications: A scalable Liquid Biopsy for HPV-related Cervical Cancer (PANEL)
Chair: Debra Fraser-Howze, D. Fraser Associates
- Belinda Nedjai, Wolfson Institute of Population Health
- Elisabeth Adams, Aquarius Population Health Limited - PMWC Showcase
- Sandrine Miller-Montgomery, Micronoma
